mProX™ Human LATS1 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1188	Magic™ Human LATS1 in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

LATS1

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

Huh7;CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research

Related Diseases

Malignant Peritoneal Mesothelioma and Tetraploidy. Among its related pathways are Hippo-Merlin signaling dysregulation and DNA IR-double strand breaks and cellular response via ATM

Gene ID

9113

UniProt ID

O95835

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The LATS1 gene in humans encodes the enzyme large tumor suppressor kinase 1 (LATS1). The Hippo signaling pathway has been linked to it, as it phosphorylates TAZ and YAP to render them inactive. A putative serine/threonine kinase that localizes to the mitotic apparatus and forms a complex with cell cycle controller CDC2 kinase during early mitosis is the protein that this gene encodes. The cell cycle determines how the protein is phosphorylated, with late prophase phosphorylation persisting until metaphase. With its binding to CDC2, the protein's N-terminal region forms a complex that exhibits decreased histone H1 kinase activity, suggesting that it functions as a negative regulator of CDC2/cyclin A. The customized LATS1 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Joseph

Reliable and repeatable LATS1 cell line. Jan 05 2021

chat Verified Customer

chat Brian

I highly recommend the human LATS1 cell line for anyone working on membrane protein research. Nov 17 2022

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 A pro-survival role of LATS1 in HCC cells in response to sorafenib treatment.

Huh7 cells were transfected with the indicated siControl and given a 72-hour treatment with either sorafenib (Srf) or DMSO vehicle. Using the appropriate antibodies, immunoblotting was used to examine cell death.

Ref: Tang, Fengyuan, et al. "LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function." Nature communications 10.1 (2019): 5755.

Pubmed: 31848340

DOI: 10.1038/s41467-019-13591-7

Research Highlights

Significant discrepancies exist in the regulatory networks governing the mRNA expression patterns of LATS1 and LATS2, which could account for variations in the protein binding partners of each kinase as well as in the subcellular regions where each kinase functions.
Furth, Noa, and Yael Aylon. "The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway." Cell Death & Differentiation 24.9 (2017): 1488-1501.
Pubmed: 28644436 DOI: 10.1038/cdd.2017.99

These results show that Src activation is the fundamental cause of YAP dysregulation in carcinogenesis and reveal tyrosine phosphorylation of LATS1 by Src as a unique mechanism of Hippo pathway control by cell adhesion.
Si, Yuan, et al. "Src inhibits the Hippo tumor suppressor pathway through tyrosine phosphorylation of Lats1." Cancer research 77.18 (2017): 4868-4880.
Pubmed: 28754671 DOI: 10.1158/0008-5472.CAN-17-0391